Abstract: A PLL includes an oscillator, a time-to-digital converter (TDC) and a system for the remaining functionality. The TDC measures the oscillator's phase against a reference clock. The measured phase has an integer part obtained from a modulus-K counter, and a fractional part measured by a fine TDC. The system compares the measured phase with a desired phase, and filters it to obtain a parameter that controls the oscillator frequency. The TDC may also include a synchronization block to align the fine TDC and a pulse hider to reduce the power used by the fine TDC. The system may include an integrator to calculate the integer part of the desired phase, a second integrator to calculate the fractional part, and an interpolator for an even finer fraction. A method to obtain fast lock includes using the phase error rate of change to control the oscillator frequency.

Abstract: A PLL includes an oscillator, multiple time-to-digital converters (TDCs) and a system for the remaining functionality. The TDCs measure the oscillator's phase against respective multiple reference clocks. The system compares the respective measured phases with respective desired phases to obtain phase error signals. One is selected to close the loop. The others are monitored and adjusted when not equal to zero. When a new reference clock must be used, the loop is changed from including the old phase error signal to the new. The old phase error was zero because the loop was in lock, the new phase error is zero because it was monitored and adjusted. Therefore, upon switching the loop from the old to the new phase error signal, the loop remains locked and switching is hitless.

Abstract: A fabric for delaying digital signals in continuous time has an array of node filters. Inputs of filters in the first column are inputs of the fabric. A node filter has a delay element and a cross-coupling element, whose output signals are added or subtracted to form an output signal of the filter. A node filter in a row is concatenated to the previous filter in the row through its delay element. Inputs of cross-coupling elements are connected to other rows of the array. Outputs of node filters form the outputs of the fabric. Delay times of delay elements and cross-coupling elements are nominally equal. Drive strengths of cross-coupling elements may be lower than drive strengths of delay elements. A delay line is constructed by combining a phase generator and a fabric, where the phase generator splits a digital input signal in multiple incrementally delayed versions for the fabric inputs.

Abstract: An apparatus and method for digital-to-analog conversion. A digital-to-analog converter includes a sampler for resampling a digital signal and a DAC array. The DAC array includes a sequencer, a unit element activator, and an array of one-bit DACs (unit elements). The unit elements are activated in a cyclical sequence, based on the resampled digital signal. Unit elements in the sequence may be skipped, based on a disruption probability. The disruption probability may be determined randomly, or pseudo-randomly. Output signals of the unit elements are summed or averaged to form an analog signal. The converter may include a filter to filter the analog signal.

Abstract: A transconductance amplifier has a pair of input terminals and a pair of output terminals. A first pair of transconductors is connected to the input terminals and the output terminals. A second pair of transconductors has inputs connected to output terminals, and outputs connected to the opposing output terminals. A third pair of transconductors has both its inputs and its outputs connected to the output terminals. One or more of the transconductors have a control port for a control signal to adjust its transconductance. The control signal may switch the transconductance of this or these transconductors between two or more values. One or more of the transconductors in the transconductance amplifier may include a tri-state inverter, which may be enabled or disabled through a control port.

Abstract: Invented is a method of treating cardiovascular disease/injury, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.

Abstract: The embodiments provide methods of administering a high dose or a loading dose of a TPO modulator to a subject. The embodiments further provide methods of treating thrombocytopenia and/or neutropenia in a subject. Additionally, the embodiments further provide methods of increasing platelet production and/or enhancing the number of peripheral blood stem cells in a subject.

Abstract: Devices, systems, and methods determine the health of oral objects by providing objective measurements using a detachable probe body. The detachable probe body may isolate reusable system components (including an electromagnetic signal detection, signal transmission, energy generation, and or energy transmitting components) from the oral cavity, optionally by encasing at least a portion of one or more of these components in a sheath or the like. A window of the probe body maintains sterile isolation and transmits electromagnetic energy to and/or signals from the oral object. Accuracy can be enhanced by a clamp or other structure for engaging a surface of the oral object so as to maintain a fixed alignment between the signal receiver and the oral object.

Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.

Abstract: Invented is a method of treating cardiovascular disease/injury, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.

Abstract: Invented is a method of treating thrombocytopenia in a human in need thereof which comprises the administration of a therapeutically effective amount of a 3?-{N?-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2?-hydroxybiphenyl-3-carboxylic acid to such human.

Abstract: A system to integrate all aspect to the operation and administration of an educational institution, including customized interfaces for different classes of users, allowing differing levels of access and functionality, including, teachers, parents, students, administrators, secretaries, and school nurses.

Abstract: The embodiments provide methods of administering a high dose or a loading dose of a TPO modulator to a subject. The embodiments further provide methods of treating thrombocytopenia and/or neutropenia in a subject. Additionally, the embodiments further provide methods of increasing platelet production and/or enhancing the number of peripheral blood stem cells in a subject.

Abstract: Invented is a method of treating viral diseases, particularly hepatitis C, in a human, in need thereof which comprises the administration of a combination of therapeutically active agents selected from a TPO receptor agonist and an antiviral therapy selected from: an alpha interferon, ribavirin, a ribavirin analog and an HCV antiviral to such human.

Abstract: Invented is a method of treating degenerative diseases/injuries, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.

Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.

Abstract: Invented is a method of treating degenerative diseases/injuries, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.

Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.

Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.

Abstract: Invented is a method of treating degenerative diseases/injuries, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.